<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127723</url>
  </required_header>
  <id_info>
    <org_study_id>31GC1202</org_study_id>
    <nct_id>NCT02127723</nct_id>
  </id_info>
  <brief_title>(Macrolane VR30) in Buttocks Reshaping and contouringCellulite (Macrolane VR30) in Buttocks Reshaping and Contouring</brief_title>
  <official_title>An Open, Non-comparative Single Center Study to Evaluate Efficacy and Safety of HA (Macrolane VR30) in Buttocks Reshaping and Contouring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most common treatments today for enhancing the shape and size of the buttocks are&#xD;
      transplantation of the patient's own body fat after liposuction and insertion of permanent&#xD;
      implants. Macrolane VRF30 is a gel product based on hyaluronic acid which is a transparent&#xD;
      slow-flowing gel. A similar hyaluronic-acid gel from the same manufacturer, Q-Med AB, has&#xD;
      been used for many years for the treatment of facial wrinkles. By injecting Macrolane gel&#xD;
      into the skin, the shape of the buttocks can be altered and their volume increased.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aesthetic dermatologists have reported promising results on the use of Macrolane VRF30 for&#xD;
      buttocks reshaping and contouring. Although treatment with Macrolane VRF is well documented&#xD;
      in breast enhancement, there is limited documentation on the use in buttocks reshaping. Based&#xD;
      on these clinical impressions, this study aims at acquiring information on the efficacy and&#xD;
      safety of Macrolane VRF30 in this particular indication. As a result of the reshaping of the&#xD;
      buttocks, it is expected that improvement of skin laxity will result in contouring and&#xD;
      reduction of cellulite. By using standardised evaluation tools, the results of buttock&#xD;
      reshaping reported anecdotally can be confirmed by accurate measurements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Aesthetic Improvement of the Buttocks Using Investigator GAIS</measure>
    <time_frame>48 weeks post treatment</time_frame>
    <description>Assess the aesthetic improvement of the buttocks after reshaping in female subjects with cellulite associated with laxity and loss of volume of the buttocks at each follow up visit after treatment using the investigator Global Aesthetic Improvement Scale (GAIS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Improvement in Cellulite Severity Compared to Baseline Using the Cellulite Severity Scale (CSS)</measure>
    <time_frame>48 weeks post treatment</time_frame>
    <description>Assess improvement of cellulite in the buttock areas compared to baseline at each follow up visit after treatment using the Cellulite Severity Scale (CSS). A scale graded 1-15 that measures the severity of cellulites. Grade 1-5 is mild; grade 6-10 is moderate; grade 11-15 is severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of CSS Responders</measure>
    <time_frame>48 weeks post treatment</time_frame>
    <description>Assess the CSS responder rate, where a responder is defined as a subject who has improved at least one grade from baseline in items A and/or B and/or D of the CSS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Related Adverse Events</measure>
    <time_frame>Until 48 weeks post treatment</time_frame>
    <description>Number of subjects with related adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cellulite of the Buttocks</condition>
  <arm_group>
    <arm_group_label>Macrolane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive hyaluronic acid injection (Macrolane VRF30)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid injection (Macrolane VRF30)</intervention_name>
    <description>Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite</description>
    <arm_group_label>Macrolane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Female subjects older than 30 years. 2. Subjects presenting with loss of contour of&#xD;
             the upper half of the buttocks, associated with skin laxity and appearance of&#xD;
             cellulite grade 1 or 2 on items A, B and D of the CSS.&#xD;
&#xD;
             3. Treatment-na√Øve subjects for fillers in the areas to be treated. 4. Subjects with&#xD;
             signed informed consent. 5. Medical history and physical examination which, based on&#xD;
             the investigator's opinion, do not prevent the subject from taking part in the study&#xD;
             and use the product under investigation.&#xD;
&#xD;
             6. Subjects should maintain their habits regarding physical activity. 7. Availability&#xD;
             of the subject throughout the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Pregnant women or women intending to get pregnant in the next 12 months. 2.&#xD;
             Subjects with known hypersensitivity to any compound of the study product or&#xD;
             anaesthesia used in the study.&#xD;
&#xD;
             3. Subjects with history of any other adverse effect, which should prevent the subject&#xD;
             from participating in the study according to the investigator's opinion.&#xD;
&#xD;
             4. Subjects participating in other clinical trials within 30 days prior to baseline.&#xD;
&#xD;
             5. Any prior surgery, any prior cosmetic procedures or side effects from previous&#xD;
             procedures in the buttocks, including permanent fillers, liposuction and prosthesis,&#xD;
             that may interfere with the results.&#xD;
&#xD;
             6. Subjects with presence of autoimmune disease or other chronic disease that in the&#xD;
             opinion of the Investigator may interfere with the outcome of the study.&#xD;
&#xD;
             7. Subjects on immunomodulatory therapy (suppressive or stimulatory). 8. Subjects with&#xD;
             active inflammation or infection in the areas to be treated. 9. Subject with bleeding&#xD;
             disorders or subjects who are taking thrombolytics or anticoagulants.&#xD;
&#xD;
             10. Subjects who have taken inhibitors of platelet aggregation, including nonsteroidal&#xD;
             anti-inflammatory agents and acetylsalicylic acid, 2 weeks before treatment.&#xD;
&#xD;
             11. Subjects with contraindications for MRI, such as presence of pacemaker, clips or&#xD;
             splinter, metal prosthesis or tendency for claustrophobia.&#xD;
&#xD;
             12. Subjects who are study site staff for this study, or close relatives of the study&#xD;
             site staff, as well as subjects who are employed by the Sponsor company, or close&#xD;
             relatives of employees at the Sponsor company.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doris Hexsel, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brazilian Center for Studies in Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Hexsel</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90570-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 29, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <results_first_submitted>December 15, 2017</results_first_submitted>
  <results_first_submitted_qc>September 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cellulite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Macrolane</title>
          <description>All subjects will be treated with Macrolane&#xD;
Hyaluronic acid injection (Macrolane VRF30): Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Macrolane</title>
          <description>Att subjects will be treated with Macrolane&#xD;
Hyaluronic acid injection (Macrolane VRF30): Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cellulite severity scale</title>
          <description>A scale graded 1-15 that measures the severity of cellulites. Grade 1-5 is mild; grade 6-10 is moderate; grade 11-15 is severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Aesthetic Improvement of the Buttocks Using Investigator GAIS</title>
        <description>Assess the aesthetic improvement of the buttocks after reshaping in female subjects with cellulite associated with laxity and loss of volume of the buttocks at each follow up visit after treatment using the investigator Global Aesthetic Improvement Scale (GAIS).</description>
        <time_frame>48 weeks post treatment</time_frame>
        <population>Global aesthetic improvement was assessed as Very much improved, Much improved, Improved, No change or Worse. Number of improved subjects (i.e. very much improved, much improved or improved) was presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Macrolane</title>
            <description>All subjects will be treated with Macrolane&#xD;
Hyaluronic acid injection (Macrolane VRF30): Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Aesthetic Improvement of the Buttocks Using Investigator GAIS</title>
          <description>Assess the aesthetic improvement of the buttocks after reshaping in female subjects with cellulite associated with laxity and loss of volume of the buttocks at each follow up visit after treatment using the investigator Global Aesthetic Improvement Scale (GAIS).</description>
          <population>Global aesthetic improvement was assessed as Very much improved, Much improved, Improved, No change or Worse. Number of improved subjects (i.e. very much improved, much improved or improved) was presented.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Improvement in Cellulite Severity Compared to Baseline Using the Cellulite Severity Scale (CSS)</title>
        <description>Assess improvement of cellulite in the buttock areas compared to baseline at each follow up visit after treatment using the Cellulite Severity Scale (CSS). A scale graded 1-15 that measures the severity of cellulites. Grade 1-5 is mild; grade 6-10 is moderate; grade 11-15 is severe.</description>
        <time_frame>48 weeks post treatment</time_frame>
        <population>Improvement in cellulite at 48 weeks compared to baseline, using the CSS and indicated by the grading reduction.</population>
        <group_list>
          <group group_id="O1">
            <title>Macrolane</title>
            <description>All subjects will be treated with Macrolane&#xD;
Hyaluronic acid injection (Macrolane VRF30): Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Improvement in Cellulite Severity Compared to Baseline Using the Cellulite Severity Scale (CSS)</title>
          <description>Assess improvement of cellulite in the buttock areas compared to baseline at each follow up visit after treatment using the Cellulite Severity Scale (CSS). A scale graded 1-15 that measures the severity of cellulites. Grade 1-5 is mild; grade 6-10 is moderate; grade 11-15 is severe.</description>
          <population>Improvement in cellulite at 48 weeks compared to baseline, using the CSS and indicated by the grading reduction.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of CSS Responders</title>
        <description>Assess the CSS responder rate, where a responder is defined as a subject who has improved at least one grade from baseline in items A and/or B and/or D of the CSS.</description>
        <time_frame>48 weeks post treatment</time_frame>
        <population>Number of subjects who were improved at least 1 grade from baseline in items A and/or B and /or D of the CSS.</population>
        <group_list>
          <group group_id="O1">
            <title>Macrolane</title>
            <description>All subjects will be treated with Macrolane&#xD;
Hyaluronic acid injection (Macrolane VRF30): Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CSS Responders</title>
          <description>Assess the CSS responder rate, where a responder is defined as a subject who has improved at least one grade from baseline in items A and/or B and/or D of the CSS.</description>
          <population>Number of subjects who were improved at least 1 grade from baseline in items A and/or B and /or D of the CSS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Related Adverse Events</title>
        <description>Number of subjects with related adverse events</description>
        <time_frame>Until 48 weeks post treatment</time_frame>
        <population>Evaluation of safety by assessment of number of related adverse events (AEs)</population>
        <group_list>
          <group group_id="O1">
            <title>Macrolane</title>
            <description>All subjects will be treated with Macrolane&#xD;
Hyaluronic acid injection (Macrolane VRF30): Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Related Adverse Events</title>
          <description>Number of subjects with related adverse events</description>
          <population>Evaluation of safety by assessment of number of related adverse events (AEs)</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Macrolane</title>
          <description>Att subjects will be treated with Macrolane&#xD;
Hyaluronic acid injection (Macrolane VRF30): Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>injection site hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>injection site puritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>injection site discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Q-Med AB</name_or_title>
      <organization>Q-Med AB</organization>
      <phone>+46 18 474 9000</phone>
      <email>medicalinfo.q-med@alderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

